Theratome Bio is a development-stage therapeutics company that leverages advanced regenerative medicine techniques enhanced by artificial intelligence. The company focuses on addressing both the causes and symptoms of diseases, particularly through the rescue and repair of tissues affected by ischemic and inflammatory challenges. A key aspect of their approach involves the use of secretomes, which are bioactive substances secreted by cells that contain proteins, micro-RNAs, exosomes, and metabolites. Theratome has developed second-generation secretomes that are optimized through specific stimulation protocols, allowing for tailored formulations that enhance therapeutic efficacy while minimizing unwanted components. 

The company is particularly focused on two main areas: extending the shelf life of transplanted organs and treating dry eye disease, which affects millions of individuals in the U.S. Their secretome product line offers significant clinical advantages, including rapid bioavailability, consistency in manufacturing, and simplified storage compared to traditional cell or tissue therapeutics. Theratome Bio aims to advance its pipeline in organ transplant preservation and dry eye disease, with potential future expansions into other conditions such as acute respiratory distress syndrome (ARDS), amyotrophic lateral sclerosis (ALS), and stroke, contingent on securing additional financial resources.

United States

Theratome Bio is a pre-clinical company developing a platform of cell-free biologics. The therapeutics cover multiple areas of unmet medical need, and offer advantages over cell-based therapies, including off-the-shelf administration, convenient freezer temperature storage and delivery, and immediate bioavailability.   Current therapeutic areas under development are ischemic brain injury, concussion, acute kidney injury, and increasing the shelf life of donor organs and tissues.

Theratome Bio

Company Details